Clinical trials: Advanced
Mesenchymal Chondrosarcoma
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
- Trial name
- ISG-MCS (NCT04305548)
- Testing
- Trabectedin
- Where
- 7 sites in Italy
- Volunteers
- 16 people
- Sponsor
- Italian Sarcoma Group
Cervical Cancers
The Effects of Immunonutrition Therapy on Locally Advanced Cervical Cancer Patients
The goal of this open-label randomized control trial is to study the effect of immunonutrition in locally advanced cervical cancer (LACC) with standard concurrent chemoradiotherapy.
- Trial name
- NCT06349148
- Testing
- enteral immunonutrition, standard oral enteral nutrition
- Where
- China
- Volunteers
- 50 people
- Sponsor
- SHUANG ZHENG JIA, PhD
Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma
Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer
This research study is examining the benefit of a novel radiation planning approach on the likelihood of developing severe esophagitis (irritation and inflammation of the esophagus) during the course of radiation therapy with…
- Trial name
- NCT02394548
- Testing
- Contralateral Esophageal Sparing Technique (CEST)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Malignant Solid Tumor
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug…
- Trial name
- NCT01606748
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Parkinson's Disease
Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease
The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose…
- Trial name
- NCT00260793
- Testing
- Ropinirole Hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Agarwal, Pinky, M.D.
Ovarian Cancer
Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy Paclitaxel and Carboplatin with Pembrolizumab in patients with advanced ovarian cancer.
- Trial name
- MITO28MaNGOov4 (NCT03410784)
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 13 sites in Italy
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute, Naples
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor…
- Trial name
- NCT01889238
- Testing
- Enzalutamide
- Where
- 132 sites in United States, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
Colorectal Neoplasms, Colonic Neoplasms
Study Evaluating EKB-569 in Advanced Colorectal Cancer
This non-randomized, open-label, outpatient clinical trial is designed to assess the safety and efficacy of daily orally administered EKB-569 in subjects with advanced colorectal cancer.
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00072748
- Testing
- EKB-569
- Volunteers
- 63 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
This study is for people with advanced cancer for which no curative treatment exists. The purpose of this study is to test the safety and effectiveness of the combination of the drugs Temsirolimus and Capecitabine and see what…
- Trial name
- NCT01050985
- Testing
- Temsirolimus and capecitabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Georgetown University
Advanced Solid Tumors
SKB118 Injection in Advanced Solid Tumors
This is a multicenter, open-label, Phase I/II clinical study. The study is divided into two parts, the SKB118 monotherapy study and the SKB118 in combination with SKB264 study.
- Trial name
- NCT07586943
- Testing
- SKB118 Injection, SKB118+SKB264
- Where
- China
- Volunteers
- 530 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Gastric Cancer
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal epithelial transition factor (MET)-positive…
- Trial name
- RILOMET-2 (NCT02137343)
- Testing
- Rilotumumab, Cisplatin, Capecitabine
- Where
- 25 sites in Japan, South Korea
- Volunteers
- 34 people
- Sponsor
- Amgen
Recession, Gingival
Clinical Evaluation of Laterally Closed Tunnel Technique Versus Coronally Advanced Flap Combined With Connective Tissue Graft for the Treatment of Isolated RT2 Gingival Recession
The aim of this study is to evaluate reduction of recession depth using lateral closed tunnel technique versus CAF technique using connective tissue graft in single RT2 gingival recession cases.
- Trial name
- NCT05823415
- Testing
- Laterally Closed Tunnel with CTG, CAF with CTG
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- British University In Egypt
Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
This phase I trial studies the safety, side effects, and best dose of ADG126, in combination with ivonescimab alone, in combination with ivonescimab, leucovorin, and fluorouracil, or in combination with ivonescimab and…
- Conditions
- Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07363408
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
- Trial name
- DUO-CRC-NK-111 (NCT07589517)
- Testing
- EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Solid Tumor, Adult, Advanced Solid Tumors
IMX-110 in Patients With Advanced Solid Tumors
Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer
- Trial name
- NCT03382340
- Testing
- Imx-110
- Where
- 2 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Immix Biopharma Australia Pty Ltd
Solid Tumor
An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM303 Injection in patients with advanced solid tumors.
- Trial name
- NCT06695689
- Testing
- LM303
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Rectal Cancer
The Effects of a 9 Week Exercise Programme on Fitness and Quality of Life in Rectal Cancer Patients After Chemoradiotherapy and Before Surgery
Patients' ability to tolerate surgery is associated with physical fitness: less fit patients have an increased rate of death and serious complications following major surgery.
- Trial name
- SRETP (NCT01914068)
- Testing
- Supervised exercise in hospital
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Non-Small-Cell Lung Cancer
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC
- Trial name
- NCT04699968
- Testing
- SHR-1701，Famitinib, SHR-1701
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Cancer
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00217711
- Testing
- Capecitabine, irinotecan hydrochloride, oxaliplatin
- Where
- 4 sites in Switzerland
- Volunteers
- 23 people
- Sponsor
- Swiss Cancer Institute